PharmaCord, Mercalis Merge in an Effort to Support the Patient Journey
The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.
PharmaCord LLC, a provider of patient services for the biopharmaceutical industry, and Mercalis, a life sciences commercialization partner, are merging to create a “total solutions provider” for the biopharma sector that is expected to offer solutions ranging from patient services to market access, in an effort to cover the entire commercialization process.
The combined company will be majority owned by funds advised by Permira, a private equity company. Robert Truckenmiller, CEO of PharmaCord, will serve as CEO of the newly combined company, while Scott Dulitz, CEO of Mercalis, will be president. Although the financial terms of the deal were not disclosed, the transaction is expected to close by Q3 2025.
When it comes to specialty meds, PharmaCord has a pulse on the patient journey by offering various services that aim to boosting awareness and simplify patient access, while improving affordability and adherence to therapy. Meanwhile, Mercalis’ goal is to collaborate with life science companies in order to provide solutions across the commercialization value chain.
“This combination is about more than growth—it’s about impact and transformation to meet evolving manufacturer and patient needs. By uniting PharmaCord’s deep expertise in hub services with Mercalis’s established leadership in end-to-end patient access solutions and robust infrastructure, we are building a next-generation platform that redefines how life science companies bring innovative therapies to market,” noted Truckenmiller. “Together, we will unlock new efficiencies, accelerate patient access, create a seamless experience for healthcare providers and patients alike, and provide a highly compelling opportunity for employees.”
The partnership is centered around augmenting the patient experience by delivering access and affordability to the specialty med space.
“This merger marks an exciting milestone for Mercalis and our team as we continue our journey of transformative growth and innovation alongside PharmaCord,” said Dulitz. “Mercalis and PharmaCord share a noble mission—to enhance the lives of the patients we serve. By joining forces, we are strengthening our ability to provide seamless, fully integrated commercialization support for our life science customers and their patients … I am truly excited about the opportunities this merger brings to our combined ecosystem and the positive impact it will have on the healthcare industry.”
References
1. PharmaCord and Mercalis to Merge, Creating Next-Generation Platform to Meet Evolving Needs of the Biopharmaceutical Industry. Business Wire. March 12, 2025. Accessed March 12, 2025. https://www.businesswire.com/news/home/20250312808363/en/PharmaCord-and-Mercalis-to-Merge-Creating-Next-Generation-Platform-to-Meet-Evolving-Needs-of-the-Biopharmaceutical-Industry
